{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:01Z","timestamp":1786118941777,"version":"build-2736575974"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/bor.0b013e328314b7b4","type":"journal-article","created":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T03:09:50Z","timestamp":1224558590000},"page":"648-655","source":"Crossref","is-referenced-by-count":60,"title":["Genetic predisposition to statin myopathy"],"prefix":"10.1097","volume":"20","author":[{"given":"Georgirene D","family":"Vladutiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-3-20210128","first-page":"50","article-title":"Pharmacogenetics, adverse drug reactions and public health","volume":"9","author":"Kollek","year":"2006","journal-title":"Community Genet"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1196\/annals.1423.020","article-title":"Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children","volume":"1110","author":"Ross","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMe0800801","article-title":"Pharmacogenomics: ready for prime time?","volume":"358","author":"Shurin","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ahj.2006.05.013","article-title":"Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey","volume":"152","author":"Ansell","year":"2006","journal-title":"Am Heart J"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann Pharmacother"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/BOR.0b013e328010c559","article-title":"Myotoxicity associated with lipid-lowering drugs","volume":"19","author":"Baer","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.bor.0000245730.25383.97","article-title":"Statin myopathy: an update","volume":"18","author":"Christopher-Stine","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MOL.0b013e328235a5a2","article-title":"Pharmacogenomics of statin response","volume":"18","author":"Mangravite","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MOL.0b013e3280555083","article-title":"Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy","volume":"18","author":"Schmitz","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"R17-3-20210128","first-page":"545","article-title":"The genetic determinants of atorvastatin response","volume":"9","author":"Rodrigues","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1345\/aph.1G035","article-title":"Differential association between statin exposure and elevated levels of creatine kinase","volume":"39","author":"Chan","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R20-3-20210128","first-page":"904","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat Rev"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1017\/S0317167100007514","article-title":"A neuromuscular approach to statin-related myotoxicity","volume":"35","author":"Baker","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin associated myopathy with normal and abnormal creatine kinase: clinical, pathological and biochemical features","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors and metabolic myopathies associated with lipid-lowering drugs","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"27C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data \u2013 2005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/mus.20525","article-title":"Familial idiopathic hyper-CK-emia: an under recognized condition","volume":"33","author":"Capasso","year":"2006","journal-title":"Muscle Nerve"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.2007.075523","article-title":"Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study","volume":"67","author":"Sailler","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy: a genomewide study.","volume":"359","year":"2008","journal-title":"New Engl J Med"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","article-title":"Pharmacogenomics of human OATP transporters","volume":"372","author":"Konig","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/14622416.6.8.865","article-title":"Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis","volume":"6","author":"Ruano","year":"2005","journal-title":"Pharmacogenomics"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Ruano","year":"2007","journal-title":"Muscle Nerve"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FPC.0b013e328012d0a9","article-title":"CYP2D6*4 polymorphism is associated with statin-induced muscle effects","volume":"17","author":"Frudakis","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneur.57.7.923","article-title":"Treatment of McArdle disease","volume":"57","author":"Haller","year":"2000","journal-title":"Arch Neurol"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.22100","article-title":"In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects","volume":"55","author":"Guis","year":"2006","journal-title":"Arth Rheum"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.22487","article-title":"Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al.","volume":"57","author":"Vladutiu","year":"2007","journal-title":"Arth Rheum"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.clpt.6100396","article-title":"Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study","volume":"83","author":"Kawashiri","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbrc.2008.04.172","article-title":"Functional characterization of human CoQ4, a gene required for Coenzyme Q10 biosynthesis","volume":"372","author":"Casarin","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1172\/JCI29089","article-title":"Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders","volume":"117","author":"Mollet","year":"2007","journal-title":"J Clin Invest"},{"key":"R45-3-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1086\/500092","article-title":"A mutation in para-hydroxybenzoate-polyprenyl transferase (CoQ2) causes primary coenzyme Q10 deficiency","volume":"78","author":"Quinzii","year":"2006","journal-title":"Am J Hum Genet"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1086\/510023","article-title":"Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations","volume":"79","author":"Lopez","year":"2006","journal-title":"Am J Hum Genet"},{"key":"R47-3-20210128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajhg.2007.12.024","article-title":"ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency","volume":"82","author":"Lagier-Tourenne","year":"2008","journal-title":"Am J Hum Genet"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/brain\/awm054","article-title":"The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene","volume":"130","author":"Gempel","year":"2007","journal-title":"Brain"},{"key":"R49-3-20210128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng1001-184","article-title":"Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene","volume":"29","author":"Date","year":"2001","journal-title":"Nat Genet"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1172\/JCI31423","article-title":"Mutations in coenzymeQ10 biosynthetic genes","volume":"117","author":"DiMauro","year":"2007","journal-title":"J Clin Invest"},{"key":"R51-3-20210128","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"R52-3-20210128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-1 associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e328314b7b4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:07:15Z","timestamp":1786036035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200811000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328314b7b4","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}